drugset
drugset / Trial / NCT01181245

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

NCT01181245 ↗

Phase 1 Completed 50 enrolled Kyntra Bio
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Objectives * Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib * Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib

Timeline

Start
2008-12
Primary completion
2014-05
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pamrevlumab Monoclonal antibody 3 mg/kg Intravenous
Subject Pamrevlumab Monoclonal antibody 10 mg/kg Intravenous
Subject Pamrevlumab Monoclonal antibody 15 mg/kg Intravenous
Subject Pamrevlumab Monoclonal antibody 17.5 mg/kg Intravenous
Subject Pamrevlumab Monoclonal antibody 22.5 mg/kg Intravenous
Subject Pamrevlumab Monoclonal antibody 25 mg/kg Intravenous
Subject Pamrevlumab Monoclonal antibody 35 mg/kg Intravenous
Subject Pamrevlumab Monoclonal antibody 45 mg/kg Intravenous

Indications

No indication recorded.